LILACS – Literatura Latinoamericana y del Caribe de Ciencias de la Salud

Modulação da concentração intracelular de NAD+ e seu efeito na tumorigênese induzida por benzo[a]pireno em células bronquiais epiteliais humanas

Cordeiro, Everson Willian Fialho.

A alta incidência, prevalência e mortalidade do câncer de pulmão demonstram a necessidade de se identificar alterações moleculares envolvidas na carcinogênese pulmonar. Nesse contexto, a reprogramação do metabolismo energético é uma marca emergente do câncer. Há evidências de que benzo[a]pi...

Neoplasias Pulmonares/patología, Carcinogénesis/efectos de los fármacos, Metabolismo Energético, Células Epiteliales/clasificación, ADN, Niacinamida/efectos adversos, Quimioprevención/clasificación, Técnicas In Vitro/métodos

Fulltext

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma

Marta, Guilherme Nader; da Fonseca, Leonardo G; Braghiroli, Maria Ignez; Moura, Fernando; Hoff, Paulo M; Sabbaga, Jorge.

Clinics; 76 (), 2021

OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. Patients were divided into ...

Antineoplásicos/efectos adversos, Carcinoma Hepatocelular/tratamiento farmacológico, Neoplasias Hepáticas/tratamiento farmacológico, Niacinamida/efectos adversos, Compuestos de Fenilurea/efectos adversos, Pronóstico, Sorafenib/efectos adversos

Fulltext

Grade III hand-foot skin reaction induced by sorafenib

Chiriac, Anca; Coros, Marius Florin; Podoleanu, Cristian; Stolnicu, Simona.

An. bras. dermatol; 92 (4), 2017

Antineoplásicos/efectos adversos, Carcinoma Hepatocelular/tratamiento farmacológico, Erupciones por Medicamentos/etiología, Erupciones por Medicamentos/patología, Eritema/inducido químicamente, Eritema/patología, Neoplasias Hepáticas/tratamiento farmacológico, Niacinamida/efectos adversos, Niacinamida/análogos & derivados, Compuestos de Fenilurea/efectos adversos, Índice de Severidad de la Enfermedad, Sorafenib

Fulltext

Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

Varghese, Joy; Kedarisetty, Chandan Kumar; Venkataraman, Jayanthi; Srinivasan, Vijaya; Deepashree, Thiruchunapalli; Uthappa, Mangerira Chinnappa; Ilankumaran, Kaliamurthy; Govil, Sanjay; Reddy, Mettu Srinivas; Rela, Mohamed.

Ann. hepatol; 16 (2), 2017

ABSTRACT Background & Aim. Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. We studied the role of combination of TACE and sorafenib in BCLC stages B/C. Material and methods. We undertook an observational study on a ...

Antineoplásicos/uso terapéutico, Carcinoma Hepatocelular/terapia, Neoplasias Hepáticas/terapia, Niacinamida/análogos & derivados, Compuestos de Fenilurea/uso terapéutico, Inhibidores de Proteínas Quinasas/uso terapéutico, Antineoplásicos/efectos adversos, Carcinoma Hepatocelular/etiología, Carcinoma Hepatocelular/mortalidad, Carcinoma Hepatocelular/patología, Quimioembolización Terapéutica/efectos adversos, Quimioembolización Terapéutica/mortalidad, Estimación de Kaplan-Meier, Neoplasias Hepáticas/etiología, Neoplasias Hepáticas/mortalidad, Estadificación de Neoplasias, Niacinamida/efectos adversos, Niacinamida/uso terapéutico, Compuestos de Fenilurea/efectos adversos, Inhibidores de Proteínas Quinasas/efectos adversos, Factores de Tiempo, Resultado del Tratamiento, Carga Tumoral

Fulltext

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

Branco, Fernanda; Alencar, Regiane S. M; Volt, Fernanda; Sartori, Giovana; Dode, Andressa; Kikuchi, Luciana; Tani, Claudia M; Chagas, Aline L; Pfiffer, Tulio; Hoff, Paulo; Carrilho, Flair J; Mattos, Angelo Alves de.

Ann. hepatol; 16 (2), 2017

ABSTRACT Background and Aims. The presence of dermatologic reaction as an adverse event to sorafenib treatment in patients with unresectable hepatocellular carcinoma has been indicated as a prognostic factor for survival in a recent prospective analysis. To date, this is the only clinical predictor of ...

Fulltext